A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...
Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.
An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients undergoing urgent surgery or experiencing major ...
Background: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding ...
The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback